文献速递老年慢病共病管理多重用药

老年2型糖尿病使用新型二线降糖药与严重低血糖风险

Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2023-01-01

本研究基于医保理赔与电子健康记录,比较65岁以上2型糖尿病患者启用SGLT2i versus DPP-4i或GLP-1RA的严重低血糖风险。经过倾向评分匹配后,SGLT2i与较低的严重低血糖风险相关,且在基线使用胰岛素或磺脲类药物的患者中关联幅度更大。按心血管疾病、慢性肾脏病和衰弱分层的结果与总体队列相似。

要点

  • 老年2型糖尿病患者启用SGLT2i versus DPP-4i,严重低血糖风险降低(HR 0.75)。
  • 启用SGLT2i versus GLP-1RA,严重低血糖风险也较低(HR 0.90)。
  • 基线使用磺脲类药物者中SGLT2i versus DPP-4i的低血糖风险降低更明显(HR 0.57)。

核心结论

  • 在65岁以上2型糖尿病患者中,与肠促胰岛素类药物相比,启用SGLT2i与较低的严重低血糖风险相关。
  • 在基线使用胰岛素或磺脲类药物的患者中,SGLT2i与DPP-4i相比的严重低血糖风险关联幅度更大。

研究设计与样本

  • 比较 Effectiveness 队列研究,使用2013年3月至2018年12月的Medicare理赔数据及Medicare链接的电子健康记录。
  • 研究对象为65岁以上、启用SGLT2i versus DPP-4i或SGLT2i versus GLP-1RA的2型糖尿病患者,经1:1倾向评分匹配后分析。
  • 严重低血糖定义为需急诊或住院就诊,采用经验证的算法识别。

主要发现

  • 基线使用胰岛素者中SGLT2i versus DPP-4i的RD大于未使用胰岛素者,但HR相似。
  • 按基线心血管疾病、慢性肾脏病和衰弱分层的结果与总体队列相似;GLP-1RA比较的结果也相似。

临床怎么用

  • 对于65岁以上2型糖尿病患者,启用SGLT2i与DPP-4i或GLP-1RA相比,严重低血糖风险较低,该信息可辅助降糖药物选择。
  • 基线使用胰岛素或磺脲类药物的老年患者中,SGLT2i与DPP-4i相比的严重低血糖风险降低幅度更大。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe hypoglycemia is associated with adverse clinical outcomes. We evaluated the risk of severe hypoglycemia in older adults initiating newer glucose-lowering medications overall and across strata of known indicators of high hypoglycemia risk. METHODS: We conducted a comparative-effectiveness cohort study of older adults aged >65 years with type 2 diabetes initiating sodium-glucose cotransporter 2 inhibitors (SGLT2i) versus dipeptidyl peptidase-4 inhibitors (DPP-4i) or SGLT2i versus glucagon-like peptide-1 receptor agonists (GLP-1RA) using Medicare claims (3/2013-12/2018) and Medicare-linked-electronic health records. We identified severe hypoglycemia requiring emergency or inpatient visits using validated algorithms. After 1:1 propensity score matching, we estimated hazard ratios (HR) and rate differences (RD) per 1,000 person-years. Analyses were stratified by baseline insulin, sulfonylurea, cardiovascular disease (CVD), chronic kidney disease (CKD), and frailty. RESULTS: Over a median follow-up of 7 (interquartile range: 4-16) months, SGLT2i was associated with a reduced risk of hypoglycemia versus DPP-4i (HR 0.75 [0.68, 0.83]; RD -3.21 [-4.29, -2.12]), and versus GLP-1RA (HR 0.90 [0.82, 0.98]; RD -1.33 [-2.44, -0.23]). RD for SGLT2i versus DPP-4i was larger in patients using baseline insulin than in those not, although HRs were similar. In patients using baseline sulfonylurea, the risk of hypoglycemia was lower in SGLT2i versus DPP-4i (HR 0.57 [0.49, 0.65], RD -6.80 [-8.43, -5.16]), while the association was near-null in those without baseline sulfonylurea. Results stratified by baseline CVD, CKD and frailty were similar to the overall cohort findings. Findings for the GLP-1RA comparison were similar. CONCLUSIONS: SGLT2i was associated with a lower hypoglycemia risk versus incretin-based medications, with larger associations in patients using baseline insulin or sulfonylurea.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Htoo PT, Paik JM, Alt E, et al. Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk. J Gerontol A Biol Sci Med Sci. 2023. PMID: 36866496. doi:10.1093/gerona/glad075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。